Monoclonal antibodies in the treatment of bronchial asthma

Abstract

The article discusses different phenotypes of heterogeneous bronchial asthma (BA), methods of identification of patients with severe bronchial asthma, based on clinical characteristics, biological and genetic markers. Definition of phenotypes/ endotypes of BA contributes to better understanding of the nature of the disease and is feasible for development of an individual approach to therapy, because some types of BA may differ in resistance response to the standard treatment. The article gives an overview of modern research focused on the use of monoclonal antibodies in the treatment of BA. It discusses the algorithm of selection of patients with severe BA for prescribing of biological therapy.